InicioHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Cierre anterior
25,85 €
Intervalo diario
25,67 € - 25,67 €
Intervalo anual
19,52 € - 36,69 €
Cap. bursátil
3584,42 M USD
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(USD) | mar 2024info | Cambio interanual |
---|---|---|
Ingresos | — | — |
Gastos operativos | 126,19 M | 28,63 % |
Ingresos netos | -125,30 M | -357,42 % |
Margen de beneficio neto | — | — |
Beneficios por acción | -1,02 | -326,67 % |
EBITDA | -121,67 M | -339,34 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
(USD) | mar 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 520,91 M | 8,30 % |
Activos totales | 955,15 M | 7,16 % |
Responsabilidades totales | 459,74 M | 7,87 % |
Patrimonio total | 495,40 M | — |
Acciones en circulación | 124,20 M | — |
Precio-valor contable | 6,63 | — |
Rentabilidad económica | -39,90 % | — |
Retorno sobre capital | -43,18 % | — |
Flujo de caja
Variación neta del flujo de caja
(USD) | mar 2024info | Cambio interanual |
---|---|---|
Ingresos netos | -125,30 M | -357,42 % |
Efectivo de operaciones | -92,38 M | -191,68 % |
Efectivo de inversión | -268,94 M | -645,70 % |
Efectivo de financiación | 430,78 M | 82.741,73 % |
Variación neta del flujo de caja | 69,49 M | 203,27 % |
Flujo de caja libre | -91,82 M | -262,49 % |
Información sobre la empresa
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Director ejecutivo
Fundación
1 ene 2004
Sitio web
Empleados
525